Analysis of Patient-Reported Symptom Response with Osimertinib (AZD9291) Treatment for Advanced Non-Small-Cell Lung Cancer

被引：0
|
作者：
Novello, Silvia [1 ]
Rudell, Katja [2 ]
Bodnar, Carolyn [2 ]
Vowler, Sarah [2 ]
Rupnik, Tina [3 ]
Ghiorghiu, Serban [2 ]
机构：
[1] Univ Turin, Dept Oncol, Turin, Italy
[2] Astrazeneca, Cambridge, England
[3] Phastar, London, England
来源：
JOURNAL OF THORACIC ONCOLOGY | 2017年 / 12卷 / 01期
关键词：
osimertinib; symptoms; Non-small-cell lung cancer; Patient-reported outcomes;
D O I：
10.1016/j.jtho.2016.11.1747
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P3.02b-080
引用
收藏
页码：S1238 / S1239
页数：2
相关论文
共 50 条
  • [31] Patient-Reported Outcomes in OAK: A Phase III Study of Atezolizumab Versus Docetaxel in Advanced Non-Small-cell Lung Cancer
    Bordoni, Rodolfo
    Ciardiello, Fortunato
    von Pawel, Joachim
    Cortinovis, Diego
    Karagiannis, Thomas
    Ballinger, Marcus
    Sandier, Alan
    Yu, Wei
    He, Pei
    Matheny, Christina
    Felizzi, Federico
    Rittmeyer, Achim
    CLINICAL LUNG CANCER, 2018, 19 (05) : 441 - +
  • [32] Increased Expression of IRE1α Associates with the Resistant Mechanism of Osimertinib (AZD9291)-resistant Non-small Cell Lung Cancer HCC827/OSIR Cells
    Tang, Zheng-Hai
    Su, Min-Xia
    Guo, Xia
    Jiang, Xiao-Ming
    Jia, Lin
    Chen, Xiuping
    Lu, Jin-Jian
    ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, 2018, 18 (04) : 550 - 555
  • [33] Advanced lung adenocarcinoma (LUAD) patient with EGFR mutations benefited from multiline combination targeted therapies after osimertinib (AZD9291) resistance: a case report
    Chen, Jingyu
    Zhao, Xueqi
    Wang, Jinlin
    Liu, Fangfang
    Zhang, Linli
    Chen, Yuan
    Chu, Qian
    TRANSLATIONAL CANCER RESEARCH, 2022,
  • [34] Patient-Reported Quality of Life and Goals of Care in the Treatment of Locally Advanced Non-small Cell Lung Cancer
    Hitchcock, K.
    Rausch-Osian, S. M.
    Kules, S.
    King, J.
    Sierra, A.
    Hiemenz, J. W.
    Ohlendorf, J.
    Minton, J.
    Marshall, K.
    Hoppe, B. S.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2017, 99 (02): : E461 - E462
  • [35] Treatment principles in advanced non-small-cell lung cancer
    Scott, CL
    Zalcberg, JR
    Irving, LB
    AUSTRALIAN AND NEW ZEALAND JOURNAL OF SURGERY, 1996, 66 (10): : 688 - 693
  • [36] Gefitinib in the treatment of advanced non-small-cell lung cancer
    Reck, Martin
    EXPERT REVIEW OF ANTICANCER THERAPY, 2009, 9 (04) : 401 - 412
  • [37] Afatinib for the treatment of advanced non-small-cell lung cancer
    Genova, Carlo
    Rijavec, Erika
    Barletta, Giulia
    Burrafato, Giovanni
    Biello, Federica
    Dal Bello, Maria Giovanna
    Coco, Simona
    Truini, Anna
    Alama, Angela
    Boccardo, Francesco
    Grossi, Francesco
    EXPERT OPINION ON PHARMACOTHERAPY, 2014, 15 (06) : 889 - 903
  • [38] Axitinib for the treatment of advanced non-small-cell lung cancer
    King, Judy W.
    Lee, Siow-Ming
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2013, 22 (06) : 765 - 773
  • [39] Advanced non-small-cell lung cancer: Benefit of chemotherapy in symptom control
    Margery, J
    Le Moulec, S
    Grassin, F
    Bauduceau, O
    Dot, JM
    Vedrine, L
    Natali, F
    Guigay, JL
    BULLETIN DU CANCER, 2003, 90 (10) : 917 - 918
  • [40] Bevacizumab for the treatment of advanced non-small-cell lung cancer
    Manegold, Christian
    EXPERT REVIEW OF ANTICANCER THERAPY, 2008, 8 (05) : 689 - 699
12345